

Amendments to the Claims

The listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

Claims 1-60. Canceled without prejudice.

61. (New) A compound which is (-)-O-desmethylvenlafaxine succinate.
62. (New) The compound of claim 61, wherein the compound is a hydrate of (-)-O-desmethylvenlafaxine succinate.
63. (New) The compound of claim 62 which is (-)-O-desmethylvenlafaxine succinate monohydrate.
64. (New) A compound which is (+)-O-desmethylvenlafaxine succinate.
65. (New) The compound of claim 64, wherein the compound is a hydrate of (+)-O-desmethylvenlafaxine succinate.
66. (New) The compound of claim 65 which is (+)-O-desmethylvenlafaxine succinate monohydrate.
67. (New) A pharmaceutical composition comprising a therapeutically effective amount of (-)-O-desmethylvenlafaxine succinate and a pharmaceutically acceptable carrier or excipient.
68. (New) A pharmaceutical dosage form comprising a therapeutically effective amount of (-)-O-desmethylvenlafaxine succinate and a pharmaceutically acceptable carrier or excipient.
69. (New) An oral dosage form comprising a therapeutically effective amount of (-) O-desmethylvenlafaxine succinate and a pharmaceutically acceptable carrier or excipient.

70. (New) The oral dosage form of claim 69, wherein the dosage form is a tablet or capsule.

71. (New) The oral dosage form of claim 69, wherein the dosage form is a sustained release formulation.

72. (New) The oral dosage form of claim 69, further comprising a rate controlling polymer material.

73. (New) The oral dosage form of claim 72, wherein the rate controlling polymer is hydropropylmethyl cellulose.

74. (New) The oral dosage form of claim 69, wherein the oral dosage form further comprises a binder.

75. (New) The oral dosage form of claim 74, wherein the binder is microcrystalline cellulose.

76. (New) A method of treating a patient suffering from depression comprising providing to a patient in need thereof an effective amount of (-)-O-desmethylvenlafaxine succinate.

77. (New) A method of treating a patient suffering from depression comprising providing to a patient in need thereof (-)-O-desmethylvenlafaxine succinate in an amount of about 10 mg to about 1000 mg per day.

78. (New) A method of treating a patient suffering from depression comprising providing to a patient in need thereof (-)-O-desmethylvenlafaxine succinate in an amount of about 50 mg to about 500 mg per day.

79. (New) A method of treating a patient suffering from depression comprising providing to a patient in need thereof (-)-O-desmethylvenlafaxine succinate in an amount of about 75 mg to about 350 mg per day.

80. (New) A method of treating a patient suffering from anxiety comprising providing to a patient in need thereof an effective amount of (-)-O-desmethylvenlafaxine succinate.

81. (New) A method of treating a patient suffering from premenstrual dysphoric disorder comprising providing to a patient in need thereof an effective amount of (-)-O-desmethylvenlafaxine succinate.

82. (New) A method of treating a patient suffering from a condition selected from attention deficit disorder, obsessive compulsory disorder, autism, schizophrenia, obesity, anorexia nervosa, bulimia nervosa, cocaine and alcohol addiction, urinary incontinence, pain, Parkinson's disease, and epilepsy comprising providing to a patient in need thereof an effective amount of (-)-O-desmethylvenlafaxine succinate.